MX2020002777A - Metodos y composiciones para tratamiento de epidermolisis ampollosa. - Google Patents

Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Info

Publication number
MX2020002777A
MX2020002777A MX2020002777A MX2020002777A MX2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
epidermolysis bullosa
bullosa
Prior art date
Application number
MX2020002777A
Other languages
English (en)
Spanish (es)
Inventor
Evangelos V Badiavas
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US12558316B2/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX2020002777A publication Critical patent/MX2020002777A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Medicinal Preparation (AREA)
MX2020002777A 2017-09-22 2018-09-21 Metodos y composiciones para tratamiento de epidermolisis ampollosa. MX2020002777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US12558316B2 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Publications (1)

Publication Number Publication Date
MX2020002777A true MX2020002777A (es) 2020-09-17

Family

ID=65810503

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002777A MX2020002777A (es) 2017-09-22 2018-09-21 Metodos y composiciones para tratamiento de epidermolisis ampollosa.
MX2022015753A MX2022015753A (es) 2017-09-22 2020-03-12 Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015753A MX2022015753A (es) 2017-09-22 2020-03-12 Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Country Status (10)

Country Link
EP (1) EP3684336A4 (fr)
JP (1) JP7525396B2 (fr)
KR (1) KR102722950B1 (fr)
CN (1) CN111182890A (fr)
AU (1) AU2018335788B2 (fr)
CA (1) CA3076610A1 (fr)
EA (1) EA202090814A1 (fr)
IL (1) IL273407B2 (fr)
MX (2) MX2020002777A (fr)
WO (1) WO2019060719A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
WO2014159662A1 (fr) 2013-03-13 2014-10-02 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
IL322149A (en) * 2019-05-03 2025-09-01 Cellphire Inc Materials and methods for manufacturing blood products
KR102125567B1 (ko) 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
AU2021327376A1 (en) * 2020-08-21 2023-04-20 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP3971440B1 (fr) 2020-09-21 2023-12-27 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
CA3217654A1 (fr) * 2021-04-23 2022-10-27 Spot Biosystems Ltd. Vesicules extracellulaires chargees de biomolecules
JP2024531238A (ja) * 2021-08-12 2024-08-29 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
US12589120B2 (en) 2021-10-12 2026-03-31 Eliksa Therapeutics, Inc. Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions
EP4694903A1 (fr) * 2023-04-11 2026-02-18 Eliksa Therapeutics, Inc. Procédés d'augmentation des niveaux de protéine thérapeutique et/ou d'amélioration de la fonction cellulaire avec des compositions de liquide amniotique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159662A1 (fr) * 2013-03-13 2014-10-02 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
WO2015038075A1 (fr) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Procédé
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
US20190133922A1 (en) * 2016-01-12 2019-05-09 Kangstem Biotech Co., Ltd. Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors
EP3402489B1 (fr) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation

Also Published As

Publication number Publication date
AU2018335788B2 (en) 2024-08-15
CA3076610A1 (fr) 2019-03-28
IL273407B2 (en) 2025-09-01
IL273407A (en) 2020-05-31
JP2020534344A (ja) 2020-11-26
MX2022015753A (es) 2023-01-19
KR102722950B1 (ko) 2024-10-28
CN111182890A (zh) 2020-05-19
EP3684336A4 (fr) 2021-06-02
AU2018335788A1 (en) 2020-03-19
JP7525396B2 (ja) 2024-07-30
IL273407B1 (en) 2025-05-01
WO2019060719A1 (fr) 2019-03-28
EA202090814A1 (ru) 2020-08-07
KR20200088799A (ko) 2020-07-23
EP3684336A1 (fr) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2020002777A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
IL275663A (en) Cancer treatment methods
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
PT3631454T (pt) Tratamento de tumores positivos para lag-3
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EP3589289A4 (fr) Inhibition de smarca2 pour le traitement du cancer
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2018010993A (es) Derivados de icariina e icaritina.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2020006297A (es) Variantes de cd19.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
CO2019014647A2 (es) Composiciones inmunogénicas
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
EP3719032A4 (fr) Composition pour la prévention ou le traitement de la chute des cheveux
SI3661510T1 (sl) Postopki zdravljenja vedenjskih sprememb
EP3691632C0 (fr) Compositions, méthodes, systèmes et/ou kits de prévention et/ou de traitement de néoplasmes
EP3677264C0 (fr) Composition pour la prévention ou le traitement de la dermatite atopique
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
SG11202005163PA (en) Methods of treating cancer